Chennai Meena

how big is Chennai Meena?

As of Jun 06, Chennai Meenakshi Multispeciality Hospital Ltd has a market capitalization of 23.52 Cr, with net sales of 34.82 Cr and a net profit of -1.37 Cr over the latest four quarters. The standalone balance sheet shows shareholder's funds of -0.33 Cr and total assets of 22.81 Cr.

As of Jun 06, Chennai Meenakshi Multispeciality Hospital Ltd has a market capitalization of 23.52 Cr, classifying it as a Micro Cap company.<BR><BR>As of Jun 06, the company reported a sum of Net Sales for the latest 4 quarters amounting to 34.82 Cr and a Net Profit of -1.37 Cr. This data is based on Standalone financials.<BR><BR>As of Mar 24, the Standalone balance sheet shows Shareholder's Funds of -0.33 Cr and Total Assets of 22.81 Cr.

What does Chennai Meena do?

Chennai Meenakshi Multispeciality Hospital Ltd, established in 1990, operates in the healthcare sector as a micro-cap company with a market cap of Rs 23 Cr. As of March 2025, it reported net sales of 9 Cr and a net profit of 0 Cr.

Overview:<BR>Chennai Meenakshi Multispeciality Hospital Ltd operates in the healthcare services industry and is categorized as a micro-cap company.<BR><BR>History:<BR>The company was incorporated in 1990 and was formerly known as Devaki Hospital Limited until its name change in October 2007. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 9 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 0 Cr (Quarterly Results - Mar 2025)<BR>- Market-cap value: Rs 23 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: N/A<BR>- Industry P/E: 54<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -4.96<BR>- Return on Equity: 98.56%<BR>- Price to Book: -16.83<BR><BR>Contact Details:<BR>- Address: New No 70 Old No 149, Luz Church Road Mylapore Chennai Tamil Nadu : 600004<BR>- Tel: 91-044-42938938<BR>- Email: cmmhospitals@gmail.com<BR>- Website: https://cmmh.in

Has Chennai Meena declared dividend?

No Dividend History Available

Who are the peers of the Chennai Meena?

Chennai Meena's peers include Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Family Care, Gian Lifecare, Vanta Bioscience, and Clinitech Lab. In terms of management risk, growth ratings, and capital structure, they vary from excellent to below average, with Chennai Meena showing a 1-year return of -2.80%.

Peers: The peers of Chennai Meena are Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Family Care, Gian Lifecare, Vanta Bioscience, Clinitech Lab.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs, while Good management risk is found at Syngene Intl., Poly Medicure, Indegene, Vijaya Diagnost., and Clinitech Lab, and Average management risk is noted at Family Care. Below Average management risk is seen at Gian Lifecare, while Vanta Bioscience and Chennai Meena do not qualify. Growth ratings show Good growth at Family Care, Average growth at Poly Medicure, Indegene, and Gian Lifecare, and Below Average growth at Syngene Intl., Dr Lal Pathlabs, Vijaya Diagnost., and Clinitech Lab, with Chennai Meena and Vanta Bioscience not qualifying. Excellent capital structure is noted for Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Family Care, and Gian Lifecare, while Good capital structure is observed at Clinitech Lab, and Chennai Meena and Vanta Bioscience do not qualify.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Poly Medicure at 24.17%, while the lowest is Vanta Bioscience at -54.78%. Chennai Meena's 1-year return is -2.80%, which is higher than Vanta Bioscience but lower than Poly Medicure. Additionally, the six-month returns for Family Care, Chennai Meena, Gian Lifecare, Vanta Bioscience, and Clinitech Lab are all negative.

Is Chennai Meena overvalued or undervalued?

As of May 31, 2024, Chennai Meena's valuation has shifted from attractive to risky due to negative financial metrics, including a PE ratio of -17.17 and an EV to EBITDA of -30.42, indicating it is overvalued and underperforming compared to peers like Max Healthcare and Apollo Hospitals, as well as the Sensex.

As of 31 May 2024, the valuation grade for Chennai Meena has moved from attractive to risky, indicating a significant deterioration in its financial health. The company appears to be overvalued based on its current metrics, with a PE ratio of -17.17, an EV to EBITDA of -30.42, and a ROCE of -11.43%. These negative ratios suggest that the company is struggling to generate profits and manage its capital effectively.<BR><BR>In comparison to its peers, Chennai Meena's valuation stands out unfavorably. For instance, Max Healthcare has a PE ratio of 100.29, while Apollo Hospitals shows a PE of 69.03, both indicating a much stronger market position. The stark contrast in valuation ratios highlights that Chennai Meena is not only underperforming but also facing significant challenges relative to its competitors. Additionally, the company's stock has underperformed the Sensex over the past year, with a return of -8.52% compared to the Sensex's 7.58%, reinforcing the notion that it is currently overvalued.

What is the technical trend for Chennai Meena?

As of May 12, 2025, Chennai Meena's technical trend is mildly bearish, influenced by bearish moving averages and Bollinger Bands, despite some mildly bullish signals in the weekly MACD and KST.

As of 12 May 2025, the technical trend for Chennai Meena has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD shows a mildly bearish trend. The Bollinger Bands are bearish on both weekly and monthly time frames, and daily moving averages are bearish. The KST reflects a mildly bullish weekly trend but is mildly bearish monthly. The Dow Theory shows a mildly bullish weekly trend with no trend on the monthly. Overall, the current technical stance is mildly bearish, influenced primarily by the bearish moving averages and Bollinger Bands, despite some mildly bullish signals in the MACD and KST on the weekly chart.

Who are in the management team of Chennai Meena?

As of March 2023, the management team of Chennai Meena consists of R Gomathi as Managing Director and K. Meyyanathan, N. Rajkumar, and Jayanthi Radhakrishnan as Independent Directors.

As of March 2023, the management team of Chennai Meena includes the following individuals:<BR><BR>1. R Gomathi - Managing Director<BR>2. K. Meyyanathan - Independent Director<BR>3. N. Rajkumar - Independent Director<BR>4. Jayanthi Radhakrishnan - Independent Director<BR><BR>R Gomathi serves as the Managing Director, while the other three members hold positions as Independent Directors.

Who are the top shareholders of the Chennai Meena?

The top shareholders of Chennai Meena are Jayanthi Radhakrishnan with 25.59%, followed by public shareholder Vijayan Abinaya at 10.06%. Individual investors own 60.51%, with no pledged promoter holdings or foreign institutional investors.

The top shareholders of Chennai Meena include Jayanthi Radhakrishnan, who holds the highest stake at 25.59%. The highest public shareholder is Vijayan Abinaya, with a holding of 10.06%. Additionally, individual investors collectively own 60.51% of the company. There are no pledged promoter holdings or foreign institutional investors involved, and mutual funds hold a small percentage through one scheme at 0.14%.

How has been the historical performance of Chennai Meena?

Chennai Meena's historical performance shows declining net sales and profits, with revenue dropping from 38.74 Cr in Mar'23 to 34.82 Cr in Mar'25, and a shift from profit to loss in operating profit and net profit. Despite these challenges, total liabilities and cash flow from operations remained stable.

Answer:<BR>The historical performance of Chennai Meena shows a fluctuating trend in its financial metrics over the years.<BR><BR>Breakdown:<BR>Chennai Meena's net sales decreased from 38.74 Cr in Mar'23 to 34.82 Cr in Mar'25, reflecting a decline in revenue. The total operating income followed a similar trend, dropping from 38.74 Cr in Mar'23 to 34.82 Cr in Mar'25. The company experienced an operating profit (PBDIT) decline, moving from 3.35 Cr in Mar'23 to a loss of 0.21 Cr in Mar'25. Consequently, the profit before tax also fell from 1.28 Cr in Mar'23 to a loss of 1.43 Cr in Mar'25, leading to a profit after tax decline from 0.89 Cr to a loss of 1.37 Cr in the same period. The company's total liabilities remained relatively stable, with a slight decrease from 22.81 Cr in Mar'24 to 22.51 Cr in Mar'25. Cash flow from operating activities remained consistent at 2.00 Cr from Mar'22 to Mar'25, while the closing cash and cash equivalents were stable at 2.00 Cr in Mar'25. Overall, Chennai Meena's financial performance indicates challenges in profitability despite stable cash flow and liabilities.

When is the next results date for Chennai Meenakshi Multispeciality Hospital Ltd?

The next results date for Chennai Meenakshi Multispeciality Hospital Ltd is 11 February 2026.

The next results date for Chennai Meenakshi Multispeciality Hospital Ltd is scheduled for 11 February 2026.

Are Chennai Meenakshi Multispeciality Hospital Ltd latest results good or bad?

Chennai Meenakshi Multispeciality Hospital Ltd's latest results show a slight improvement with a net profit of ₹0.15 crores and a 17.35% revenue growth, but concerns remain due to a thin operating margin of 3.17% and a negative book value per share of ₹-2.53, indicating ongoing financial instability. Caution is advised as the company continues to face challenges in achieving sustainable profitability.

Chennai Meenakshi Multispeciality Hospital Ltd's latest results present a mixed picture. On one hand, the company reported a net profit of ₹0.15 crores in Q2 FY26, which is a positive turnaround from a loss of ₹0.74 crores in the previous quarter (Q1 FY26). Additionally, revenue grew by 17.35% year-on-year, reaching ₹9.47 crores, indicating some operational improvement.<BR><BR>However, the overall financial health of the company raises significant concerns. The operating margin remains very thin at just 3.17%, and the company has a negative book value per share of ₹-2.53, reflecting a distressed balance sheet with negative shareholder equity. This situation suggests that while there has been a short-term improvement in profitability, the underlying financial structure is precarious, with ongoing challenges in achieving sustainable profitability.<BR><BR>The volatility in quarterly performance, with previous losses and a weak balance sheet, indicates that the company is still struggling to stabilize its operations. Therefore, while the latest results show some positive developments, the broader context suggests caution due to the company's financial instability and high-risk profile.

Should I buy, sell or hold Chennai Meenakshi Multispeciality Hospital Ltd?

Why is Chennai Meenakshi Multispeciality Hospital Ltd falling/rising?

As of 02-Apr, Chennai Meenakshi Multispeciality Hospital Ltd's stock price is rising to 33.90, but it has a year-to-date decline of 26.29% and faces significant challenges such as a negative book value and high debt-to-equity ratio, indicating caution for potential investors.

As of 02-Apr, Chennai Meenakshi Multispeciality Hospital Ltd's stock price is rising, currently at 33.90, reflecting a change of 0.93 (2.82%) upward. This increase comes after a trend reversal, as the stock has gained following three consecutive days of decline. Additionally, it has outperformed its sector by 2.95% today, indicating a positive performance relative to its peers.<BR><BR>However, despite this short-term rise, the stock has shown a negative performance over longer periods, with a year-to-date decline of 26.29% and a one-month drop of 11.44%. The stock is also trading below its moving averages across various time frames, suggesting a generally bearish trend. Furthermore, there has been a notable decrease in investor participation, with delivery volume falling by 25.43% against the five-day average, which could indicate waning interest among investors.<BR><BR>While the stock has managed to generate a 9.57% return over the past year, outperforming the broader market, it faces significant challenges, including a negative book value and a high debt-to-equity ratio. These factors contribute to a perception of risk, as the company has recorded a negative EBITDA and has shown poor long-term growth metrics. Thus, while the stock is currently rising, the underlying fundamentals suggest caution for potential investors.

Which are the latest news on Chennai Meena?